PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6
about
Genomic analysis to guide choice of treatment for smoking cessationPhenome-wide association study for CYP2A6 alleles: rs113288603 is associated with hearing loss symptoms in elderly smokersDisposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activityGenome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries.Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokersThe role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalystPopulation Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).Cytochrome P450 pharmacogenetics in African populations.Requirements for comprehensive pharmacogenetic genotyping platforms.Evaluation of a Novel Difficulty of Smoking Cessation Phenotype Based on Number of Quit Attempts.CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.Variation in CYP2A6 Activity and Personalized Medicine.Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.Commentary on Chen et al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation?
P2860
Q24188234-48926FD0-D96A-47EF-8BDA-2ADB21141921Q33682133-4A9AE35F-15F8-4DE5-BB10-8D67C9F6E503Q36968374-333851A5-388A-4089-A731-A061E32CF6BDQ37163230-AB0E9C38-13AF-423B-AD64-79FA3FBA0390Q37325457-D483FE9D-818D-4A05-9FBD-1B5D7E47D39FQ37422732-FFD5AEC9-8A84-405C-87F5-6E7040DB7143Q37538760-69C22BE1-5FA2-4C71-A15A-6E5A03E08AADQ37625427-026657AE-97F3-402B-B8A6-81B0DD0A31D5Q38099372-CF48EFB2-464E-4F30-B17E-622F369DEB2AQ38859829-63332F08-8696-42B4-A1AB-C2454DA4B2DEQ40581457-CAF573C7-9566-44FC-86D0-EC2E1D6EC649Q41927477-F676AE10-7A9F-45AB-8288-BDA5269255B5Q43585637-FEA42CD0-EE2C-43AA-9A6E-F1872CBEB4D3Q46297334-D39B8860-A42B-425E-994B-F05A5D2EA9BFQ47163198-B97905F0-75CB-41D9-92BD-0326F46E3D0EQ48015634-4FBFA0D9-1CAF-4016-9809-2F014E1C3254Q52303929-E7613604-0477-4871-B97A-F197F833778A
P2860
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@ast
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@en
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@nl
type
label
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@ast
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@en
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@nl
prefLabel
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@ast
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@en
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@nl
P2093
P2860
P50
P3181
P1476
PharmGKB summary: very import ...... 2, subfamily A, polypeptide 6
@en
P2093
Catherine Wassenaar
Rachel F. Tyndale
Sean P. David
Teri E. Klein
P2860
P304
P3181
P356
10.1097/FPC.0B013E3283540217
P407
P577
2012-09-01T00:00:00Z